New Drug Approvals

Home » ANTIBODIES » Stelara (ustekinumab) Receives FDA Approval to Treat Active Psoriatic Arthritis

Stelara (ustekinumab) Receives FDA Approval to Treat Active Psoriatic Arthritis

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Recent Posts

Blog Stats

  • 4,043,793 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,752 other followers

add to any

Share

Ustekinumab

CAS No: 815610-63-0
Molecular Weight: 145.64 g/mol
Chemical Formula: C9H18N2O2
IUPAC Name: Immunoglobulin G1, anti-(human interleukin 12 p40 subunit) (human monoclonal CNTO 1275 gamma1-chain), disulfide with human monoclonal CNTO 1275 kappa-chain, dimer

HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ — Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. It is estimated that more than two million people in the U.S. are living with psoriatic arthritis, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions

read all at

http://www.drugs.com/newdrugs/stelara-ustekinumab-receives-fda-approval-active-psoriatic-arthritis-3903.html

Ustekinumab  (INN, experimental name CNTO 1275, proprietary commercial name StelaraCentocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.

Ustekinumab is a fully human monoclonal antibody (mAb) targeting the interleukin (IL)-12/23p40 subunit.

Interleukins are  small soluble proteins that communicate between white blood cells (leukocytes), such as T cells. Interleukins mediate the differentiation, proliferation and many other processes of these cells. IL-12 and IL-23 are involved in the differentiation of naive T cells into T helper (Th) 1 and Th17 cells respectively.

Th1 and Th17 cells have been implicated in several autoimmune disorders, such as psoriasis. Ustekinumab targets the common p40 subunit of IL-12 and IL-23 to stop these cytokines from binding to their receptors and consequently preventing the development of Th1 and Th17 cells in an immune response.

In two Phase III trials for moderate to severe psoriasis, the longest >76 weeks, ustekinumab was safe and effective.

A third Phase III trial, ACCEPT, compared the efficacy and safety of ustekinumab with etanercept in the treatment of moderate to severe plaque psoriasis. This trial found a significantly higher clinical response with ustekinumab over the 12-week study period compared to high-dose etanercept. It also demonstrated the clinical benefit of ustekinumab among patients who failed to respond to etanercept.

Ustekinumab is approved in Canada, Europe and the United States to treat moderate to severe plaque psoriasis.

As of November 2009, the drug is being investigated for the treatment of psoriatic arthritis. It has also been tested in Phase II studies for multiple sclerosis and sarcoidosis, the latter versus golimumab (Simponi).

The US Food and Drug Administration (FDA) and European Union (EU) have approved the interleukin (IL) 12/23 inhibitor ustekinumab (Stelara, Janssen Biotech) for adults with active psoriatic arthritis who have not responded adequately to previous nonbiological disease-modifying antirheumatic drug therapy, the company announced today.

Approval of ustekinumab for psoriatic arthritis is “significant for patients and physicians as it marks the first treatment approved for this devastating and complex disease since the introduction of anti-TNF biologic medicines more than a decade ago,” Jerome A. Boscia, MD, vice president and head of immunology development, Janssen Research & Development, LLC, said in a statement.

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of ustekinumab for active psoriatic arthritis in June, as reported by Medscape Medical News.

Ustekinumab is already approved in the US and EU for treatment of moderate to severe psoriatic plaques in adults. The drug, which can be used alone or in combination with methotrexate, is novel in that it targets both IL-12 and IL-23.

Image source: Crystal structure of human IL-12, Wikipedia, public domain

Ustekinumab binding to IL-12/23p40


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,752 other followers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

  • RT @aasiri: #جائزة_نوبل في #الفيزياء لعام ٢٠٢٢ لثلاثة علماء 14 hours ago
  • RT @OPRD_ACS: Process chemists from @boehringerus report an efficient asymmetric synthesis of a chiral tetrahydropyran, a key intermediate… 1 day ago
  • RT @visitmaldives: Maldives holiday resort which is perfect for for families and EVERYTHING included. #WorldsLeadingDestination2021 #Maldi1 day ago
  • RT @weddingsutra: Bollywood stars @therichachadha and @alifazal9 wed in a beautiful, intimate ceremony in his home town Lucknow, planned by… 1 day ago
  • Teaching Some classroom pictures 📸 https://t.co/7drMwQCvMc 1 day ago
  • RT @aasiri: علاقة المتشكلات R و S مع بعضها البعض. الثلاثة اشكال الموضحة بالصورة لنفس المركب مع تشكلات مختلفة حول المركز الكيرالي. عند تع… 1 day ago
  • RT @aasiri: اعلان انشاء مجتمع "الكيمياء" الجميع مدعو للدخول إلى مجتمع "الكيمياء". هدف إنشاءه هو نشر محتوى راقي ومتخصص بالاتجاهات الحديثة… 1 day ago
  • RT @aasiri: حدد نوع التشكل R او S حول المركز الكيرالي للمركبات التالية #الكيمياء #معلومات_كيميائية #الكيمياء_في_حياتنا #الكيمياء_العضوية… 1 day ago
  • RT @csir_ncl: प्रेस विज्ञप्ति: सीएसआईआर- राष्‍ट्रीय रासायनिक प्रयोगशाला (एनसीएल) में राजभाषा हिन्‍दी पखवाड़ा समारोह का आयोजन @CSIR_IND @Ash1 day ago
  • RT @SciUp: Development of a Telescoped Alkylation/Reduction Reaction Sequence and an Asymmetric Hydrogenation to Enable the Kilogram Synthe… 1 day ago
  • RT @aasiri: الكيرالية Chirality الذرة الكيرالية هي الذرة التي تحتوي على اربع مجموعات مختلفة. هناك قواعد لتحديد كون المركب التشكل R او S.… 2 days ago
  • RT @csiriiim: @csiriiim celebrates the 81st #foundation day of @CSIR_IND. Prof. Amitabha Chattopadhyay, CSIR Bhatnagar Fellow was the chief… 2 days ago
  • RT @csiriict: सीएसआईआर-भारतीय रासायनिक प्रौद्योगिकी संस्थान (सीएसआईआर-आईआईसीटी), हैदराबाद में दिनांक 03 अक्टूबर, 2022 को हिंदी पखवाड़ा समाप… 2 days ago
  • Glenmark Pharmaceuticals Ltd up for five straight sessions mybs.in/2b1JA6t 2 days ago
  • RT @csir_ncl: 30 सितंबर 2022 को हिन्दी पखवाड़ा समारोह पुरस्कार वितरण एवं एनसीएल आलोक पत्रिका विमोचन कार्यक्रम का आयोजन किया गया, जिसमें मु… 2 days ago

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: